Skip to content

H.R. 1375 · 118th Congress (2023–2025)

EFFECTIVE Act

This bill specifies that the Food and Drug Administration may deny an application for a new opioid analgesic drug (i.e., opioid medication) upon a determination that the drug does not provide a significant advantage with respect to safety or effectiveness as compared to other drugs.

Show official title

To allow the Secretary of Health and Human Services to deny approval of a new drug application for an opioid analgesic drug on the basis of such drug not being clinically superior to other commercially available drugs.

Expired in House committee

Derived from the legislative history, not an official disposition.

Latest actionReferred to Health

This bill’s path

This is H.R. 1375’s recorded path, not a universal congressional workflow.

How bills become lawAll actions
  1. Introduced

  2. Passed House

  3. Passed Senate

  4. Sent to President

  5. Signed into law

  6. Expired

Sponsor
Rep. David J. Trone (D-MD-6)
Cosponsors
5 cosponsors

1 original · 4 later

  1. Rep. Daniel Meuser (R-PA-9)· Original · Mar 3, 2023
  2. Rep. Ann M. Kuster (D-NH-2)· Later · Mar 23, 2023
  3. Rep. Daniel T. Kildee (D-MI-8)· Later · Mar 27, 2023
  4. Rep. Josh Harder (D-CA-9)· Later · Apr 13, 2023
  5. Rep. Brittany Pettersen (D-CO-7)· Later · Jun 20, 2023
Policy area
Health

On this page

Timeline

i

In chronological order. Major procedural acts are shown in full. Committee work and ordinary amendments fold in place where they happened, so they do not jump the sequence or stretch the timeline.

  1. Introduced in House

    Document: Introduced in House

    Sources
  2. Latest
    ▸ 2 committee actions · Mar 3, 2023 – Mar 10, 2023
    1. Referred to committee

      Referred to the House Committee on Energy and Commerce.

      Sources
    2. Referred to Health

      Referred to the Subcommittee on Health.

      Sources
  3. Expired

    Introduced → Referred to House Health → No further action before the 118th Congress ended.

Committees

  1. HouseEnergy and CommerceReferred Mar 3, 2023
  2. HouseHealthReferred Mar 10, 2023

Text & titles

i

Each distinct name Congress.gov recorded, once. Official, short, display, and popular titles stay distinct when the wording differs. The same wording is not repeated for every text version.

Text versions
VersionDateLinks
Introduced in House
Titles (3)
  1. EFFECTIVE Act

    Display title, Short title · Introduced in House

  2. Ensuring the FDA Fully Examines Clinical Trial Impact and Vitalness before Endorsement Act

    Short title · Introduced in House

  3. To allow the Secretary of Health and Human Services to deny approval of a new drug application for an opioid analgesic drug on the basis of such drug not being clinically superior to other commercially available drugs.

    Official title · Introduced in House